3 November 2015
EMA/PRAC/727372/2015
Procedure Management and Committees Support Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 03-06 November 2015

Chair: June Raine – Vice-Chair: Almath Spooner

03 November 2015, 13:00 – 19:00, room 3/A

04 November 2015, 08:30 – 19:00, room 3/A

05 November 2015, 08:30 – 19:00, room 3/A

06 November 2015, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

22 October 2015, 10:00 – 12:00, room 6/B, via teleconference

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 03-06 November 2015. See November 2015 PRAC minutes (to be published post December 2015 PRAC meeting).

1.2. Adoption of agenda of the meeting of 03-06 November 2015

1.3. Adoption of the minutes of the previous meeting of 05-08 October 2015

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

2.4. Planned public hearings

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

3.2.1. Inhaled corticosteroids (ICS)-containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease: beclomethasone (NAP); beclomethasone, formoterol (NAP); budesonide (NAP); budesonide, formoterol – BIRESP SPIROMAX (CAP); BUDESONIDE FORMOTEROL TEVA (CAP); DUORESP SPIROMAX (CAP); VYALER SPIROMAX (CAP); flunisolide,

salbutamol (NAP); fluticasone (NAP); fluticasone, salmeterol (NAP); fluticasone, vilanterol – RELVAR ELLIPTA (CAP); REVINTY ELLIPTA (CAP) – EMEA/H/A-31/1415

Applicant: Glaxo Group Ltd, Teva Pharma B.V., Teva Pharmaceuticals Europe, various

PRAC Rapporteur: Rafe Suvarna; PRAC Co-rapporteur: Jan Neuhauser

Scope: Review of the benefit-risk balance following notification by the European Commission of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data
Action: For adoption of a list of outstanding issues (LoOI)

3.2.2. Natalizumab – TYSABRI (CAP) - EMEA/H/A-20/1416

Applicant: Biogen Idec Ltd

PRAC Rapporteur: Brigitte Keller-Stanislawski; PRAC Co-rapporteur: Carmela Macchiarulo

Scope: Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20(8) of Regulation (EC) No 726/2004, based on pharmacovigilance data
Action: For adoption of a list of experts for the Scientific Advisory Group (SAG)

3.3. Procedures for finalisation

3.3.1. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP)
Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) – GARDASIL (CAP), SILGARD (CAP)
Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) – GARDASIL 9 (CAP) - EMEA/H/A-20/1421

Applicant: GlaxoSmithKline Biologicals S.A. (Cervarix), Sanofi Pasteur MSD SNC (Gardasil, Gardasil 9), Merck Sharp & Dohme Limited (Silgard)

PRAC Rapporteur: Julie Williams; PRAC Co-rapporteurs: Jean-Michel Dogné, Qun-Ying Yue

Scope: Review to further clarify the safety profile of human papillomavirus vaccines following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data
Action: For adoption of a recommendation to CHMP

3.4. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

None

3.5. Others

None

4. Signals assessment and prioritisation[1]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Axitinib – INLYTA (CAP)

Applicant: Pfizer Limited

PRAC Rapporteur: Ingebjorg Buajordet

Scope: Signal of nephrotic syndrome
Action: For adoption of PRAC recommendation
EPITT 18484 – New signal
Lead Member State: NO

4.1.1. Bevacizumab – AVASTIN (CAP)

Applicant: Roche Registration Ltd

PRAC Rapporteur: Doris Stenver

Scope: Signal of generalised tonic-clonic seizures
Action: For adoption of PRAC recommendation
EPITT 18485 – New signal
Lead Member State: DK

4.1.2. Human normal immunoglobulin – FLEBOGAMMA DIF (CAP); HIZENTRA (CAP); HYQVIA (CAP); KIOVIG (CAP); PRIVIGEN (CAP), NAP

Applicant: Instituto Grifols S.A. (Flebogamma DIF); CSL Behring GmbH (Hizentra, Hyqvia); Baxalta Innovations GmbH (Kiovig); Baxter AG (Privigen); various

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Signal of posterior reversible encephalopathy syndrome (PRES)
Action: For adoption of PRAC recommendation
EPITT 18512– New signal
Lead Member State: DE

4.1.3. Mercaptopurine - XALUPRINE (CAP); NAP

Applicant: Nova Laboratories Limited; Aspen Pharma; various

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Signal of lymphoproliferative disorders
Action: For adoption of PRAC recommendation
EPITT 18503– New signal
Lead Member State: SE

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

4.1.4. Somatropin - NUTROPINAQ (CAP); OMNITROPE (CAP); SOMATROPIN BIOPARTNERS (CAP), NAP

Applicant: Ipsen Pharma; Sandoz GmbH; BioPartners GmbH; various

PRAC Rapporteur: to be appointed

Scope: Signal of hypersensitivity reactions
Action: For adoption of PRAC recommendation
EPITT 18486 – New signal
Lead Member State(s): DK, DE, NL

4.1.5. Tigecycline – TYGACIL (CAP)

Applicant: Pfizer Limited

PRAC Rapporteur: Miguel-Angel Macia

Scope: Signal of hypofibrinogenaemia
Action: For adoption of PRAC recommendation
EPITT 18479 – New signal
Lead Member State: ES

4.2. New signals detected from other sources

4.2.1. Methotrexate (NAP)

Applicant: various

PRAC Rapporteur: To be appointed

Scope: Signal of congenital cardiovascular anomaly
Action: For adoption of PRAC recommendation
EPITT 18481 – New signal
Lead Member State(s): DK

4.2.2. Selective serotonin reuptake inhibitors (SSRIs): citalopram (NAP); escitalopram (NAP); fluoxetine (NAP); fluvoxamine (NAP); paroxetine (NAP); sertraline (NAP)

Applicant: various

PRAC Rapporteur: To be appointed

Scope: Signal of new malformative risks in newborn and of risk of autism spectrum disorders (ASD) after maternal use of SSRI
Action: For adoption of PRAC recommendation
EPITT 14082 – New signal
Lead Member State(s): DK, FR, NL, SE, UK

4.3. Signals follow-up and prioritisation

4.3.1. Aflibercept - EYLEA (CAP) – EMEA/H/C/002392/SDA/012

Applicant: Bayer Pharma AG

PRAC Rapporteur: Isabelle Robine

Scope: Signal of higher systemic exposure compared to ranibizumab after intravitreal injection

Action: For adoption of PRAC recommendation
EPITT 18112 – Follow-up to March 2015

4.3.2. Human fibrinogen, human thrombin – TACHOSIL (CAP) - EMEA/H/C/000505/SDA/041

Applicant: Takeda Austria GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Signal of intestinal obstruction
Action: For adoption of PRAC recommendation
EPITT 18373 – Follow-up to July 2015

4.3.3. Oxybutynin – KENTERA (CAP) - EMEA/H/C/000532/SDA/021

Applicant: Nicobrand Limited

PRAC Rapporteur: Veerle Verlinden

Scope: Signal of psychiatric disorders
Action: For adoption of PRAC recommendation
EPITT 18342 – Follow-up to June 2015

4.3.4. Palifermin – KEPIVANCE (CAP) - EMEA/H/C/000609/SDA/054

Applicant: Swedish Orphan Biovitrum AB

PRAC Rapporteur: Rafe Suvarna

Scope: Signal of infection
Action: For adoption of PRAC recommendation
EPITT 18401 – Follow-up to July 2015

4.3.5. Warfarin (NAP)

Applicant: various

PRAC Rapporteur: Torbjörn Callreus

Scope: Signal of bone density decrease
Action: For adoption of PRAC recommendation
EPITT 18173 – Follow-up to July 2015

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Albutrepenonacog alfa - EMEA/H/C/003955, Orphan

Applicant: CSL Behring GmbH

Scope: Prophylaxis and treatment of bleeding in all patients with haemophilia
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Amlodipine, valsartan - EMEA/H/C/004037

Generic

Scope: Treatment of essential hypertension
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Betulae cortex dry extract - EMEA/H/C/003938

Scope: Treatment of partial thickness wounds
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Brivaracetam - EMEA/H/C/003898

Scope: Treatment of partial-onset seizures
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Elotuzumab - EMEA/H/C/003967, Orphan

Applicant: Bristol-Myers Squibb

Scope: Treatment of myeloma
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Eptifibatide - EMEA/H/C/004104

Generic

Scope: Prevention of early myocardial infarction
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Etanercept - EMEA/H/C/004007

Scope: Treatment of arthritis
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Factor X - EMEA/H/C/003855, Orphan

Applicant: Bio Products Laboratory

Scope: Treatment of factor X deficiency
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. Ferric maltol - EMEA/H/C/002733

Scope: Treatment of iron deficiency anaemia
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. Grazoprevir, elbasvir - EMEA/H/C/004126

Scope: Treatment of chronic hepatitis C (CHC) in adults
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.11. Mercaptamine - EMEA/H/C/004038, Orphan

Applicant: Lucane Pharma

Scope: Treatment of corneal cystine deposits
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.12. Mercaptamine - EMEA/H/C/003769, Orphan

Applicant: Orphan Europe S.A.R.L.

Scope: Treatment of corneal cystine deposits
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.13. Necitumumab - EMEA/H/C/003886

Scope: Treatment of squamous non-small cell lung cancer
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.14. Opicapone - EMEA/H/C/002790

Scope: Treatment of Parkinson's disease and motor fluctuations
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.15. Pegaspargase - EMEA/H/C/003789

Scope: Combination therapy in acute lymphoblastic leukaemia (ALL)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.16. Pemetrexed - EMEA/H/C/004072

Generic

Scope: Treatment of unresectable malignant pleural mesothelioma
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.17. Pitolisant - EMEA/H/C/002616, Orphan

Applicant: Bioprojet Pharma

Scope: Treatment of narcolepsy
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.18. Recombinant L-asparaginase - EMEA/H/C/002661, Orphan

Applicant: Medac Gesellschaft fuer klinische Spezialpraeparate mbH

Scope: Combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Meningococcal group B vaccine (rDNA, component, adsorbed) – BEXSERO (CAP) - EMEA/H/C/002333/II/0033

Applicant: GSK Vaccines S.r.l

PRAC Rapporteur: Qun-Ying Yue

Scope: Submission of a revised RMP in order to replace study V72_39OB to monitor the use of Bexsero during pregnancy using the vaccines in pregnancy surveillance system, with study V72_82OB using the United States pregnancy registry
Action: For adoption of PRAC AR

5.2.2. Orlistat – ALLI (CAP) - EMEA/H/C/000854/II/0052

Applicant: Glaxo Group Ltd

PRAC Rapporteur: Rafe Suvarna

Scope: Submission of a revised RMP in order to update the safety concerns, pharmacovigilance plan and risk minimisations measures and to replace PASS study RH01159 (Survey 4) with PASS study 204675
Action: For adoption of PRAC AR

5.2.3. Sevelamer – RENAGEL (CAP) - EMEA/H/C/000254/WS/0803; RENVELA (CAP) - EMEA/H/C/000993/WS/0803; SEVELAMER CARBONATE ZENTIVA (CAP) - EMEA/H/C/003971/WS/0803; TASERMITY (CAP) - EMEA/H/C/003968/WS/0803

Applicant: Genzyme Europe BV

PRAC Rapporteur: Veerle Verlinden

Scope: Update of the RMPs to reflect a single list of safety concerns for both sevelamer formulations as per the PRAC request, as the safety profile of both compounds is similar; list of safety concerns in the RMP aligned with the list of safety concerns of the PBRER as per the PRAC request; two formulations (sevelamer hydrochloride and sevelamer carbonate) in one single RMP document; addition of minimisation measures reflecting the agreement of a single list of safety concerns for both sevelamer formulations are simplified; educational material proposed addressing the prevention of vitamin deficiency for both sevelamer formulations; addition as a newly identified safety concerns, the risk of 'hypersensitivity reactions, including angioedema and anaphylactic reactions'
Action: For adoption of PRAC AR

5.2.4. Tenofovir disoproxil – VIREAD (CAP) - EMEA/H/C/000419/II/0154/G

Applicant: Gilead Sciences International Ltd

PRAC Rapporteur: Isabelle Robine

Scope: Update of the RMP to remove the pharmacokinetic (PK) sub-study of the category 3 study GSUS-174-0144. Update of the RMP to change the agreed due date of the category 3 study GS-US-236-0103. Update of the RMP to update in Part II the Antiretroviral Pregnancy Registry exposure in line with EMA request. Update of the RMP to reflect the milestones for category 3 studies GS-US-174-0115 and GS-US-174-0144 in line with those already agreed in the PIP. In addition, the MAH took the opportunity of this procedure to update studies and exposure data as well as update status/milestones of several studies. The updated RMP version 19 is provided
Action: For adoption of PRAC AR

5.2.5. Zoledronic acid – ACLASTA (CAP) - EMEA/H/C/000595/II/0056

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of the RMP (version 11.0) in order to introduce a patient reminder card as an additional risk minimisation measure for the existing identified risk of osteonecrosis of the jaw and to propose indicators to measure the effectiveness of this new measure
Action: For adoption of PRAC AR

5.2.6. Zoledronic acid – ZOMETA (CAP) - EMEA/H/C/000336/II/0069

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Doris Stenver

Scope: Update of the RMP to reflect the PSUR data approved in procedure EMEA/H/C/PSUSA/00003149/201408 and to include an additional new minimisation measure (introduction of the reminder card in osteonecrosis of the jaw (ONJ)) as well as to propose indicators to measure its effectiveness. The MAH also took the opportunity to add the targeted follow-up checklist for the identified risk hypocalcaemia in the RMP
Action: For adoption of PRAC AR

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Ambrisentan – VOLIBRIS (CAP) - EMEA/H/C/000839/II/0039

Applicant: Glaxo Group Ltd

PRAC Rapporteur: Dolores Montero Corominas

Scope: Update of section 4.4 of the SmPC in relation to the current recommendations for liver function and section 5.1 of the SmPC with data on aminotransferase abnormalities from an analysis of the clinical study report (CSR) for PASS 'AMB110094 (VOLT)'. The current 'healthcare professional information' in Annex II has been updated accordingly as well as the Package Leaflet and RMP (version 6)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Bivalirudin – ANGIOX (CAP) - EMEA/H/C/000562/II/0062

Applicant: The Medicines Company UK Ltd.

PRAC Rapporteur: Julie Williams

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to update posology instructions and update warning of use of bivalirudin in case of haemorrhage. The Package Leaflet is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Bromfenac – YELLOX (CAP) - EMEA/H/C/000098/R/0014

Applicant: PharmaSwiss Ceska Republika s.r.o

PRAC Rapporteur: Torbjorn Callreus

Scope: Evaluation of an RMP in the context of a 5-year renewal of the marketing authorisation
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Daclatasvir – DAKLINZA (CAP) - EMEA/H/C/003768/II/0010/G

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Margarida Guimarães

Scope: Update of sections 4.2, 4.4, 4.8, 5.1and 5.2 in order to update the safety information based on final results of clinical study AI444216 (ALLY-2): 'phase 3 evaluation of daclatasvir plus sofosbuvir in treatment-naive and treatment experienced chronic hepatitis C (genotype 1, 2, 3, 4, 5, or 6) subjects coinfected with human immunodeficiency virus (HIV)'. The Package Leaflet is updated accordingly. In addition, update of sections 4.2, 4.4, 4.8, 5.1, 5.2 in order to update the safety information based on the final results of clinical study AI444215 (ALLY-1): 'phase 3 evaluation of daclatasvir, sofosbuvir, and ribavirin in genotype 1-6 chronic hepatitis C infection subjects with cirrhosis who may require future liver transplant and subjects post-liver transplant'. The Package Leaflet is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Deferasirox – EXJADE (CAP) - EMEA/H/C/000670/X/0043

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Corinne Fechant

Scope: Line extension application for a new pharmaceutical form and new strengths (90, 180 and 360 mg film-coated tablets)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Denosumab – XGEVA (CAP) - EMEA/H/C/002173/II/0041

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.4 and 4.8 of the SmPC regarding the risk of off-treatment hypercalcaemia following cessation of Xgeva treatment in young patients with growing skeletons. The Package Leaflet is updated accordingly. The RMP (version 15.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed) – HEXACIMA (CAP) - EMEA/H/C/002702/WS/0789; HEXAXIM (Art 58[2]) - EMEA/H/W/002495/WS/0789; HEXYON (CAP) - EMEA/H/C/002796/WS/0789

Applicant: Sanofi Pasteur

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of section 4.8 of the SmPC, upon request by PRAC following the assessment of PSUSA/10091/201410, to include the adverse drug reactions (ADRs) 'convulsion with or without fever' and 'anaphylactic reaction'. The Package Leaflet has been updated accordingly. The RMP (version 10.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

[2] Article 58 of Regulation (EC) No 726/2004 allows the Agency's Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO), on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

5.3.8. Eltrombopag – REVOLADE (CAP) - EMEA/H/C/001110/X/0022/G

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Dolores Montero Corominas

Scope: Extension of indication for paediatric (age 1 year and above) chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who had an insufficient response to other treatments (e.g. corticosteroids, immunoglobulins). Grouping with line extension for one new tablet strength (12.5mg) and a new powder for oral suspension formulation (25mg)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Eribulin – HALAVEN (CAP) - EMEA/H/C/002084/II/0028

Applicant: Eisai Europe Ltd.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include a new indication for Halaven 0.44 mg/ml solution for injection to expand its use to the treatment of soft tissue sarcoma, following the outcome of a Phase 3 study, Study 309. As a consequence, sections 4.1, 4.4, 4.8, and 5.1 of the SmPC are updated in order to update the safety information. The Package Leaflet and RMP are updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Eslicarbazepine acetate – ZEBINIX (CAP) - EMEA/H/C/000988/X/0050/G

Applicant: Bial - Portela & Cª, S.A.

PRAC Rapporteur: Martin Huber

Scope: Grouping of a line extension application to add a new pharmaceutical form (50 mg/ml oral suspension) and a type II to add treatment of children aged 2 years and older. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated and the Package Leaflet has been updated accordingly. The RMP (version 14.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Etanercept – ENBREL (CAP) - EMEA/H/C/000262/II/0184

Applicant: Pfizer Limited

PRAC Rapporteur: Rafe Suvarna

Scope: Update of section 4.6 of the SmPC in order to update the information on the effects of etanercept on pregnancy and lactation. The Package Leaflet and the RMP are updated accordingly. In addition, the MAH took the opportunity to update the RMP in reference to past approved variations
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Everolimus – AFINITOR (CAP) - EMEA/H/C/001038/II/0048

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include a new indication for the treatment of unresectable or metastatic, well-differentiated non-functional neuroendocrine tumours of gastrointestinal

or lung origin in adults with progressive disease for Afinitor. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Everolimus – VOTUBIA (CAP) - EMEA/H/C/002311/II/0039

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.8 (for dispersible tablets) and section 4.8 and 5.2 (for tablets) of the SmPC in order to update the safety and efficacy information with the data from the final clinical study report (CSR) comprising the extension phase of study M2302 in fulfilment of PAM (ANX 027). The Annex II and Package Leaflet are updated accordingly. In addition, the MAH updated section 4.2 and 4.4 of the SmPC in order to align with Afinitor SmPC. Moreover, the RMP (version 11.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Golimumab – SIMPONI (CAP) - EMEA/H/C/000992/II/0065/G

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information based on review of all available safety data. The Package Leaflet and RMP are updated accordingly. Additionally, the due date for a category 3 study in the RMP is proposed to be updated
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Golimumab – SIMPONI (CAP) - EMEA/H/C/000992/II/0063

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of the SmPC sections 4.2 and 5.1 in order to reflect the data from a multicentre, placebo-controlled, double-blind, randomised-withdrawal, parallel group study (GO KIDS) in children (2 to 17 years of age) with active polyarticular juvenile idiopathic arthritis (pJIA). The Package leaflet is proposed to be updated accordingly. The RMP is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Human coagulation factor VIII, human von Willebrand factor – VONCENTO (CAP) - EMEA/H/C/002493/II/0017/G

Applicant: CSL Behring GmbH

PRAC Rapporteur: Sabine Straus

Scope: Update of section 4.8 of the SmPC in order to update the frequencies of undesirable effects to reflect the final clinical study data from study CSLCT-BIO-08-53 in haemophilia A paediatric patients. The Package Leaflet is updated accordingly. The submission of the final clinical study report (CSR) CSLCT-BIO-08-53 also leads to changes to the RMP (version 6.1) in order to update the company core safety information (CCSI). In addition, submission of a revised RMP in order to remove the commitment to conduct a post-marketing study for haemophilia A patients (CSLCT-BIO-12-78) for Voncento as consequence of new data from study CSLCT-BIO-08-53
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Human fibrinogen, human thrombin – EVICEL (CAP) - EMEA/H/C/000898/II/0032

Applicant: Omrix Biopharmaceuticals N. V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of the SmPC sections 4.2 and 5.1 in order to reflect data from a multicentre, placebo-controlled, double-blind, randomised-withdrawal, parallel group study (GO KIDS) in children (2 to 17 years of age) with active polyarticular juvenile idiopathic arthritis (pJIA). The Package leaflet is proposed to be updated accordingly. The RMP is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP) - EMEA/H/C/000721/II/0067

Applicant: GlaxoSmithKline Biologicals

PRAC Rapporteur: Jean-Michel Dogné

Scope: Extension of indication to include prevention against premalignant anal lesions and anal cancer as of 9 years of age for Cervarix. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (version 11.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Human rotavirus, live attenuated – ROTARIX (CAP) - EMEA/H/C/000639/II/0078

Applicant: GlaxoSmithKline Biologicals S.A.

PRAC Rapporteur: Jean-Michel Dogné

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Ibrutinib – IMBRUVICA (CAP) - EMEA/H/C/003791/II/0013

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Julie Williams

Scope: Update of SmPC sections 4.8 and 4.9 with information on hepatic failure and hepatotoxicity. The Package Leaflet and RMP are updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Liraglutide – SAXENDA (CAP) - EMEA/H/C/003780/II/0006

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final report on the assessment of breast cancer cases found in trial NN8022-1839 (Phase 3a clinical trial). This fulfils MEA 004 listed in the RMP as an additional category 3 pharmacovigilance study. The results of the study do not require an update of the product information
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Meningococcal group a, c, w135 and y conjugate vaccine – MENVEO (CAP) - EMEA/H/C/001095/II/0056

Applicant: GSK Vaccines S.r.l

PRAC Rapporteur: Menno van der Elst

Scope: Update of section 4.8 of the SmPC in order to add 'facial paresis' as an adverse drug reaction and to provide further safety information based on the final clinical study report (CSR) of study V59_34OB in order to fulfil the post-authorisation measure (MEA 023). The Package Leaflet is updated accordingly. Moreover, the RMP (version 8.2) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Natalizumab – TYSABRI (CAP) - EMEA/H/C/000603/II/0077

Applicant: Biogen Idec Ltd

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Extension of indication to include treatment of adults with highly active relapsing remitting multiple sclerosis with high disease activity despite treatment with at least one modifying therapy (DMT). As a consequence, sections 4.1 and 4.4 of the SmPC are updated in order to provide physicians with more options for treating relapsing remitting multiple sclerosis (RRMS) patients with high disease activity who fail an initial disease modifying therapy (DMT). Consequential changes to SmPC sections 4.2, 4.3, 5.1 and Package Leaflet are submitted accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Nivolumab – NIVOLUMAB BMS (CAP) - EMEA/H/C/003840/II/0001

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of sections 4.4 and 4.8 of the SmPC to include safety information regarding the adverse drug reactions (ADR) toxic epidermal necrolysis (TEN) and encephalitis. The Package Leaflet and the RMP (version 1.3) are updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Olaparib – LYNPARZA (CAP) - EMEA/H/C/003726/II/0001/G

Applicant: AstraZeneca AB

PRAC Rapporteur: Carmela Macchiarulo

Scope: Update of sections 4.4, 4.5 and 4.6 of the SmPC in order to include further information related to pharmacokinetic interactions based on the in vivo interaction study D0816C00008, 3 in vitro interaction studies (ADME-AZS-Wave3-140714, ADME-AZS-Wave3-140725 and 140483) and data from previously submitted interaction studies. The provision of the final clinical study report (CSR) of study D0816C00008 addresses the post-authorisation measure MEA 004. Furthermore, the MAH provided the study report of in vitro study 8305083 as part of the application. In addition, the MAH took the opportunity to add the published ATC code in section 5.1 of the SmPC, and to implement minor editorial changes in the SmPC, labelling and Package Leaflet. A revised RMP (version 6) was provided as part of the application, which includes consequential changes related to data on interactions. Further, the MAH is taking the opportunity to update the due dates for the provision of the final study reports of the category 3 studies D0816C00005 and D0816C00006, and to add the new category 3 study D0816C00010
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Pembrolizumab – KEYTRUDA (CAP) - EMEA/H/C/003820/II/0002

Applicant: Merck Sharp & Dohme Limited

PRAC Rapporteur: Sabine Straus

Scope: Update of sections 4.8, 5.1 and 5.2 of the SmPC with safety and pharmacokinetic (PK) data based on the clinical study report (CSR) of study P006v01. Further, the adverse drug reaction (ADR) Guillain-Barré syndrome (GBS) has been added to sections 4.4 and 4.8 of the SmPC. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to revise the text referring to fatal cases of pneumonitis in section 4.4 of the SmPC, to implement minor editorial changes in the annexes. The RMP (version 2.0) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Perampanel – FYCOMPA (CAP) - EMEA/H/C/002434/II/0023

Applicant: Eisai Europe Ltd.

PRAC Rapporteur: Julie Williams

Scope: Update of sections 4.5 and 5.2 in order to update the safety information based on the results of a mass balance study
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Pyronaridine – PYRAMAX (Art 58) - EMEA/H/W/002319/II/0002

Applicant: Shin Poong Pharmaceutical Co., Ltd.

PRAC Rapporteur: Isabelle Robine

Scope: Update of SmPC section 4.1 to remove restrictions on repeated course of treatment in any individual and use only in areas of low transmission with evidence of artesmisinin resistance, based on further clinical experience. Consequent changes in SmPC sections 4.2, 4.4, 4.8 and the Package Leaflet are also included. A recommended change is made to SmPC Section 4.2 in relation to dosing in mild to moderate renal impairment
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Pyronaridine – PYRAMAX (Art 58) - EMEA/H/W/002319/X/0008/G

Applicant: Shin Poong Pharmaceutical Co., Ltd.

PRAC Rapporteur: Isabelle Robine

Scope: Line extension to add a new paediatric formulation 60 mg/20 mg granules for oral suspension. The product information for the 180 mg/60 mg film coated tablets has also been updated with data submitted for the line extension
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Shingles (herpes zoster) vaccine (live) – ZOSTAVAX (CAP) - EMEA/H/C/000674/R/0096

Applicant: Sanofi Pasteur MSD SNC

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of an RMP in the context of a 5-year renewal of the marketing authorisation
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Teduglutide – REVESTIVE (CAP) - EMEA/H/C/002345/II/0020

Applicant: NPS Pharma Holdings Limited

PRAC Rapporteur: Torbjorn Callreus

Scope: Extension of indication to include paediatric population. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated in order to update the safety information. The Package Leaflet is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.32. Ticagrelor – BRILIQUE (CAP) - EMEA/H/C/001241/X/0029/G

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Line extension for a new strength of 60 mg with a new indication realting to history of myocardial infarction. Further, update of the product information of the exisitng 90 mg presentation with important clinical information from the PEGASUS study
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR procedures including centrally authorised products (CAPs) only

6.1.1. Abiraterone – ZYTIGA (CAP) - PSUSA/00015/201504

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Dolores Montero Corominas

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.2. Alipogene tiparvovec – GLYBERA (CAP) - PSUSA/10056/201504

Applicant: uniQure biopharma B.V.

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.3. Alogliptin – VIPIDIA (CAP); alogliptin, metformin - VIPDOMET (CAP); alogliptin, pioglitazone – INCRESYNC (CAP) - PSUSA/10061/201504

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Menno van der Elst

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.4. Bazedoxifene, estrogens conjugated – DUAVIVE (CAP) - PSUSA/10321/201504

Applicant: Pfizer Limited

PRAC Rapporteur: Martin Huber

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.5. Bortezomib – VELCADE (CAP) - PSUSA/00424/201504

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Carmela Macchiarulo

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.6. Budesonide, formoterol fumarate dihydrate – BIRESP SPIROMAX (CAP), BUDESONIDE/FORMOTEROL TEVA (CAP), BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. (CAP), DUORESP SPIROMAX (CAP), VYLAER SPIROMAX (CAP) - PSUSA/10202/201504

Applicant: Teva Pharma B.V.

PRAC Rapporteur: Torbjorn Callreus

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.7. Cabozantinib – COMETRIQ (CAP) - PSUSA/10180/201503

Applicant: TMC Pharma Services Ltd

PRAC Rapporteur: Sabine Straus

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.8. Catumaxomab – REMOVAB (CAP) - PSUSA/00581/201504

Applicant: Neovii Biotech GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.9. Ceftaroline fosamil – ZINFORO (CAP) - PSUSA/10013/201504

Applicant: AstraZeneca AB

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.10. Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins – CHONDROCELECT (CAP) - PSUSA/00273/201504

Applicant: TiGenix NV

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.11. Conestat alfa – RUCONEST (CAP) - PSUSA/00873/201504

Applicant: Pharming Group N.V

PRAC Rapporteur: Rafe Suvarna

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.12. Defibrotide – DEFITELIO (CAP) - PSUSA/10086/201504

Applicant: Gentium S.p.A.

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.13. Delamanid – DELTYBA (CAP) - PSUSA/10213/201504

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Rafe Suvarna

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.14. Dihydroartemisinin, piperaquine tetraphosphate – EURARTESIM (CAP) - PSUSA/01069/201504

Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.15. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed) – HEXACIMA (CAP), HEXAXIM (Art 58), HEXYON (CAP) - PSUSA/10091/201504

Applicant: Sanofi Pasteur

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.16. Empagliflozin – JARDIANCE (CAP) - PSUSA/10219/201504

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Miguel-Angel Macia

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.17. Febuxostat – ADENURIC (CAP) - PSUSA/01353/201504

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Jan Neuhauser

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.18. Fenofibrate, pravastatin – PRAVAFENIX (CAP) - PSUSA/01363/201504

Applicant: Laboratoires SMB S.A.

PRAC Rapporteur: Corinne Fechant

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.19. Florbetapir (^{18}F) – AMYVID (CAP) - PSUSA/10032/201504

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Valerie Strassmann

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.20. Flutemetamol (^{18}F) – VIZAMYL (CAP) - PSUSA/10293/201504

Applicant: GE Healthcare Ltd

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.21. Granisetron – SANCUSO (CAP) - PSUSA/10101/201504

Applicant: ProStrakan Limited

PRAC Rapporteur: Jolanta Gulbinovic

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.22. Histamine – CEPLENE (CAP) - PSUSA/01610/201504

Applicant: Meda AB

PRAC Rapporteur: Almath Spooner

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.23. Ibrutinib – IMBRUVICA (CAP) - PSUSA/10301/201504

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.24. Influenza vaccine (split virion, inactivated) – IDFLU (CAP), INTANZA (CAP) - PSUSA/01743/201504

Applicant: Sanofi Pasteur

PRAC Rapporteur: Miguel-Angel Macia

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.25. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU (CAP) - PSUSA/01745/201504

Applicant: Novartis Influenza Vaccines Marburg GmbH

PRAC Rapporteur: Menno van der Elst

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.26. Insulin glulisine – APIDRA (CAP) - PSUSA/01752/201504

Applicant: Sanofi-aventis Deutschland GmbH

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.27. Ivabradine – CORLENTOR (CAP), PROCORALAN (CAP) - PSUSA/01799/201504

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Menno van der Elst

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.28. Laronidase – ALDURAZYME (CAP) - PSUSA/01830/201504

Applicant: Genzyme Europe BV

PRAC Rapporteur: Rafe Suvarna

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.29. Ledipasvir, sofosbuvir – HARVONI (CAP) - PSUSA/10306/201504

Applicant: Gilead Sciences International Ltd

PRAC Rapporteur: Margarida Guimarães

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.30. Lurasidone – LATUDA (CAP) - PSUSA/10114/201504

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Qun-Ying Yue

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.31. Macitentan – OPSUMIT (CAP) - PSUSA/10115/201504

Applicant: Actelion Registration Ltd.

PRAC Rapporteur: Dolores Montero Corominas

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.32. Mannitol – BRONCHITOL (CAP) - PSUSA/09226/201504

Applicant: Pharmaxis Pharmaceuticals Limited

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action n: Adoption of recommendation to CHMP

6.1.33. Meningococcal group a, c, w135 and y conjugate vaccine – NIMENRIX (CAP) - PSUSA/10044/201504

Applicant: GlaxoSmithKline Biologicals S.A.

PRAC Rapporteur: Rafe Suvarna

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.34. Nintedanib – OFEV (CAP) - PSUSA/10319/201504

Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG

PRAC Rapporteur: Viola Macolic Sarinic

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.35. Obinutuzumab – GAZYVARO (CAP) - PSUSA/10279/201504

Applicant: Roche Registration Ltd

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.36. Ocriplasmin – JETREA (CAP) - PSUSA/10122/201504

Applicant: ThromboGenics NV

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.37. Ofatumumab – ARZERRA (CAP) - PSUSA/02202/201504

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Doris Stenver

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.38. Para-aminosalicylic acid – GRANUPAS (CAP) - PSUSA/10171/201504

Applicant: Lucane Pharma

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.39. Propranolol – HEMANGIOL (CAP) - PSUSA/10250/201504

Applicant: Pierre Fabre Dermatologie

PRAC Rapporteur: Dolores Montero Corominas

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.40. Ramucirumab – CYRAMZA (CAP) - PSUSA/10323/201504

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.41. Regadenoson – RAPISCAN (CAP) - PSUSA/02616/201504

Applicant: Rapidscan Pharma Solutions EU Ltd.

PRAC Rapporteur: Julie Williams

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.42. Siltuximab – SYLVANT (CAP) - PSUSA/10254/201504

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.43. Sunitinib – SUTENT (CAP) - PSUSA/02833/201504

Applicant: Pfizer Limited

PRAC Rapporteur: Carmela Macchiarulo

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.44. Temsirolimus – TORISEL (CAP) - PSUSA/02887/201503

Applicant: Pfizer Limited

PRAC Rapporteur: Jean-Michel Dogné

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.45. Thiotepa – TEPADINA (CAP) - PSUSA/02932/201503

Applicant: Adienne S.r.l. S.U.

PRAC Rapporteur: Corinne Fechant

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.46. Tocilizumab – ROACTEMRA (CAP) - PSUSA/02980/201504

Applicant: Roche Registration Limited

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.47. Turoctocog alfa – NOVOEIGHT (CAP) - PSUSA/10138/201504

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.48. Umeclidinium bromide – INCRUSE (CAP) - PSUSA/10263/201504

Applicant: Glaxo Group Ltd

PRAC Rapporteur: Carmela Macchiarulo

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.49. Vandetanib – CAPRELSA (CAP) - PSUSA/09327/201504

Applicant: AstraZeneca AB

PRAC Rapporteur: Corinne Fechant

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.1.50. Yttrium (^{90}Y) chloride – YTRACIS (CAP), YTTRIGA (CAP) - PSUSA/03137/201503

Applicant: Cis Bio International

PRAC Rapporteur: Sabine Straus

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.2. PSUR procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Bimatoprost – LUMIGAN (CAP), NAP - PSUSA/00413/201503

Applicant: Allergan Pharmaceuticals Ireland

PRAC Rapporteur: Torbjorn Callreus

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.2.2. Telmisartan - MICARDIS (CAP), KINZALMONO (CAP), PRITOR (CAP), NAP hydrochlorothiazide, telmisartan – KINZALKOMB (CAP), MICARDISPLUS (CAP), PRITORPLUS (CAP) - PSUSA/02882/201504

Applicant: Bayer Pharma AG

PRAC Rapporteur: Carmela Macchiarulo

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.2.3. Tenofovir – VIREAD (CAP), NAP - PSUSA/02892/201503

Applicant: Gilead Sciences International Ltd

PRAC Rapporteur: Isabelle Robine

Scope of procedure: Evaluation of a PSUSA procedure
Action: Adoption of recommendation to CHMP

6.3. PSUR procedures including nationally authorised products (NAPs) only

6.3.1. Cabergoline (NAP) - PSUSA/00477/201503

Applicant: various

PRAC Lead: Carmela Macchiarulo

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.2. Calcium chloride, glutamic acid, glutathione, histidine, lactobionic acid, magnesium chloride, mannitol, potassium chloride, sodium hydroxide (NAP) - PSUSA/09162/201503

Applicant: various

PRAC Lead: Maria Popova-Kiradjieva

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.3. Dobutamine (NAP) - PSUSA/01151/201503

Applicant: various

PRAC Lead: Corinne Fechant

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.4. Latanoprost (paediatric indication) (NAP) - PSUSA/01834/201504

Applicant: various

PRAC Lead: Julie Williams

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.5. Nitrazepam (NAP) - PSUSA/02170/201503

Applicant: various

PRAC Lead: Doris Stenver

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.6. Pimecrolimus (NAP) - PSUSA/02411/201503

Applicant: various

PRAC Lead: Doris Stenver

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.7. Spironolactone (NAP) - PSUSA/02780/201503

Applicant: various

PRAC Lead: Kirsti Villikka

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.8. Triamcinolone (intraocular formulations) (NAP) - PSUSA/10292/201503

Applicant: various

PRAC Lead: Julie Williams

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.9. Trandolapril, verapamil (NAP) - PSUSA/03005/201503

Applicant: various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBP), poliomyelitis (inactivated) (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed) – INFANRIX HEXA (CAP) - EMEA/H/C/000296/LEG 116

Applicant: GlaxoSmithKline Biologicals

PRAC Rapporteur: Jean-Michel Dogné

Scope: Following the recommendation of the PSUR single assessment procedure adopted at PRAC in May 2015(PSUSA/00001122/201410), submission of additional information on the recently observed increase in the reported cases of regression of psychomotor development and a cumulative review of cases in relation with lack of reconstitution
Action: For adoption of advice to CHMP

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[3]

7.1.1. Deferasirox – EXJADE (CAP) - EMEA/H/C/PSP/0010.4.A.1

Applicant: Novartis Europharm Ltd.

PRAC Rapporteur: Corinne Fechant

Scope: Evaluation of a revised PASS protocol for study CICL670E2422: observational cohort study in paediatric non transfusion dependant-thalassaemia (NTDT) patients over 10 years
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Hydroxyethyl starch (NAP) - EMEA/H/N/PSP/0024.1

Applicant: B. Braun Melsungen AG

PRAC Rapporteur: Qun-Ying Yue

Scope: Revised PASS protocol (drug utilisation study) to assess the effectiveness of the risk minimisation taken following the European Commission decision dated 19 December 2013 for the referral procedure EMEA/H/A-107i/1376
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Tolvaptan – JINARC (CAP) - EMEA/H/C/PSP/0028.1

Applicant: Otsuka Pharmaceutical Europe Ltd

PRAC Rapporteur: Julie Williams

Scope: Revised PASS protocol for a prospective study of the safety of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) patients with an additional retrospective component to assess for risks associated with long term use
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[4]

7.2.1. Alemtuzumab – LEMTRADA (CAP) - EMEA/H/C/003718/MEA/005

Applicant: Genzyme Therapeutics Ltd

PRAC Rapporteur: Torbjorn Callreus

Scope: Protocol for a knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe alemtuzumab

[3] In accordance with Article 107n of Directive 2001/83/EC
[4] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

Action: For adoption of advice to CHMP

7.2.2. Insulin lispro – HUMALOG (CAP) - EMEA/H/C/000088/MEA/025.2; LIPROLOG (CAP) - EMEA/H/C/000393/MEA/018.2

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Julie Williams

Scope: Evaluation of MAH's responses to a request for supplementary information for MEA 025.1 [protocol synopsis for PASS study examining the effectiveness of risk minimisation on 200 units strength] as adopted in June 2015
Action: For adoption of advice to CHMP

7.2.3. Interferon beta-1a – AVONEX (CAP) - EMEA/H/C/000102/MEA/084.3

Applicant: Biogen Idec

PRAC Rapporteur: Dolores Montero Corominas

Scope: MAH's responses to REC 084.2 [PASS protocol] following the adoption of a request for supplementary information (RSI) as adopted in May 2015: pregnancy outcomes in multiple sclerosis populations exposed and unexposed to interferon-beta – a register-based study in the Nordic countries
Action: For adoption of advice to CHMP

7.2.4. Interferon beta-1a – REBIF (CAP) - EMEA/H/C/000136/MEA/039.3

Applicant: Merck Serono Europe Limited

PRAC Rapporteur: Qun-Ying Yue

Scope: MAH's response to MEA 039.2 [PASS protocol] following the adoption of a request for supplementary information (RSI) as adopted in May 2015: pregnancy outcomes in multiple sclerosis populations exposed and unexposed to interferon-beta – a register-based study in the Nordic countries
Action: For adoption of advice to CHMP

7.2.5. Interferon beta-1b – BETAFERON (CAP) - EMEA/H/C/000081/MEA/021.3

Applicant: Bayer Pharma AG

PRAC Rapporteur: Julie Williams

Scope: MAH's response to REC 021.2 [PASS protocol] following the adoption of a request for supplementary information (RSI) as adopted in May 2015: pregnancy outcomes in multiple sclerosis populations exposed and unexposed to interferon-beta – a register-based study in the Nordic countries
Action: For adoption of advice to CHMP

7.2.6. Interferon beta-1b – EXTAVIA (CAP) - EMEA/H/C/000933/MEA/019.3

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Julie Williams

Scope: MAH's responses to MEA 019.2 [PASS potocol] RSI as adopted in May 2015: pregnancy outcomes in multiple sclerosis populations exposed and unexposed to interferon-beta – a register-based study in the Nordic countries
Action: For adoption of advice to CHMP

7.2.7. Linaclotide – CONSTELLA (CAP) - EMEA/H/C/002490/MEA/009.2

Applicant: Almirall S.A

PRAC Rapporteur: Valerie Strassmann

Scope: MAH's responses to MEA 009.1 [revised protocol for linaclotide safety study for the assessment of diarrhoea - complications and associated risk factors in selected European populations with irritable bowel syndrome with constipation (IBS-C)] as adopted in July 2015
Action: For adoption of advice to CHMP

7.2.8. Naloxegol – MOVENTIG (CAP) - EMEA/H/C/002810/MEA/002.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Almath Spooner

Scope: MAH's responses to MEA 002 [revised protocol for naloxegol post-market observational drug utilisation study (study D2288R00081)] as adopted in May 2015
Action: For adoption of advice to CHMP

7.2.9. Naloxegol – MOVENTIG (CAP) - EMEA/H/C/002810/MEA/004.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Almath Spooner

Scope: MAH's responses to MEA 004 [revised protocol for naloxegol observational safety study in patients taking opioids for cancer pain (study D2288R00082)] as adopted in May 2015
Action: For adoption of advice to CHMP

7.2.10. Naloxegol – MOVENTIG (CAP) - EMEA/H/C/002810/MEA/006.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Almath Spooner

Scope: MAH's responses to MEA 006 [revised protocol for naloxegol observational safety study in patients taking opioids for non-cancer pain (study D2288R00084)] as adopted in May 2015
Action: For adoption of advice to CHMP

7.2.11. Naltrexone, bupropion – MYSIMBA (CAP) - EMEA/H/C/003687/MEA 003

Applicant: Orexigen Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Drug utilisation study (DUS): PASS protocol for a retrospective chart review and nested naltrexone/bupropion (NB) prescribing physician cross sectional survey
Action: For adoption of advice to CHMP

7.2.12. Naltrexone, bupropion – MYSIMBA (CAP) - EMEA/H/C/003687/MEA 004

Applicant: Orexigen Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: PASS protocol for the naltrexone/bupropion observational database study
Action: For adoption of advice to CHMP

7.2.13. Nivolumab – NIVOLUMAB BMS (CAP) - EMEA/H/C/003840/MEA/007; OPDIVO (CAP) - EMEA/H/C/003985/MEA/008

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Protocol for study CA209234, a non-interventional category 3 PASS: pattern of use, safety, and effectiveness of nivolumab in routine oncology practice
Action: For adoption of advice to CHMP

7.2.14. Olaparib – LYNPARZA (CAP) - EMEA/H/C/003726/MEA/011.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Carmela Macchiarulo

Scope: MEA's responses to MEA 011 [revised synopsis protocol for a study to collect and/or retrieve prospective data from sizeable patient cohorts with ovarian cancer, representing real world evidence from relevant countries] as adopted in June 2015
Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[5]

None

7.4. Results of PASS non-imposed in the marketing authorisation(s)[6]

7.4.1. Dexmedetomidine – DEXDOR (CAP) - EMEA/H/C/002268/II/0014 (without RMP)

Applicant: Orion Corporation

PRAC Rapporteur: Julie Williams

Scope: Submission of the final study report of DexDUS (study 3005021): a multinational, observational study to investigate the use of dexmedetomidine (Dexdor) in clinical practice with a focus to characterise the use in the paediatric population
Action: For adoption of PRAC Assessment Report

7.4.2. Fondaparinux sodium – ARIXTRA (CAP) - EMEA/H/C/000403/II/0067 (with RMP)

Applicant: Aspen Pharma Trading Limited

PRAC Rapporteur: Qun-Ying Yue

Scope: Submission of the final study report for WE115280: Physician adherence to fondaparinux prescribing information for patients with superficial vein thrombosis (SVT) of the lower limbs. There is no change to the product information based on the outcome and conclusions of this study
Action: For adoption of PRAC Assessment Report

[5] In accordance with Article 107p-q of Directive 2001/83/EC
[6] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

7.4.3. Memantine – AXURA (CAP) - EMEA/H/C/000378/WS/0804; EBIXA (CAP) - EMEA/H/C/000463/WS/0804; MEMANTINE MERZ (CAP) - EMEA/H/C/002711/WS/0804 (with RMP)

Applicant: Merz Pharmaceuticals GmbH, H. Lundbeck A/S

PRAC Rapporteur: Dolores Montero Corominas

Scope: Submission of the final results of a non-interventional PASS to examine the use of memantine and risk of prostate cancer (nationwide case-control studies in Denmark and Sweden) in order to fulfil MEA 31.5. The RMP (version 8.0) has been updated: 1) to delete the important potential risk 'prostate cancer' based on the results of case control studies, 2) to delete the important identified risk 'overdose with pump device' based on the PSUR 16 PRAC AR and 3) to update clinical trial exposure and post-authorization experience
Action: For adoption of PRAC Assessment Report

7.4.4. Panitumumab – VECTIBIX (CAP) - EMEA/H/C/000741/II/0071 (with RMP)

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Julie Williams

Scope: Submission of the final study report study 20101121 (category 3): study to measure the effectiveness of the risk minimisation measures. A revised RMP (version 17) has been provided to reflect the results of the study, as well as general updates of clinical / post-marketing data in line with a new DLP and current product information
Action: For adoption of PRAC Assessment Report

7.4.5. Tenofovir disoproxil – VIREAD (CAP) - EMEA/H/C/000419/WS0731/0147 (with RMP)
tenofovir disoproxil, emtricitabine – EVIPLERA (CAP) - EMEA/H/C/002312/WS0731/0056; TRUVADA (CAP) - EMEA/H/C/000594/WS0731/0113 - (with RMP)
tenofovir disoproxil, emtricitabine, efavirenz – ATRIPLA (CAP) - EMEA/H/C/000797/WS0731/0101 (with RMP)
tenofovir disoproxil, emtricitabine, elvitegravir, cobicistat – STRIBILD (CAP) - EMEA/H/C/002574/WS0731/0044 (with RMP)

Applicant: Bristol-Myers Squibb and Gilead Sciences International Ltd

PRAC Rapporteur: Isabelle Robine (Viread); Julie Williams (Truvada), Martin Huber (Atripla), Menno van der Elst (Eviplera), Rafe Suvarna (Stribild)

Scope: Submission of the final clinical study report for Viread study GS-US-104-0423 'phase 4 cross-sectional study of bone mineral density in human immunodeficiency virus (HIV)-1 infected subjects' in fulfilment of a post-authorisation measure (PAM) for Viread, Truvada, Eviplera, Stribild and Atripla (category 3 additional pharmacovigilance activity for Viread, Truvada, Eviplera and Stribild, and category 4 for Atripla). The RMP for each product is updated accordingly
Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation[7]

7.5.1. Adalimumab – HUMIRA (CAP) - EMEA/H/C/000481/MEA 046.5

Applicant: AbbVie Ltd.

[7] In line with the revised variations regulation for any submission before 4 August 2013

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Sixth year interim report from a registry in juvenile idiopathic arthritis (JIA) patients
Action: For adoption of advice to CHMP

7.5.2. Adalimumab – HUMIRA (CAP) - EMEA/H/C/000481/MEA 075.4

Applicant: AbbVie Ltd.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Third annual progress report for a long-term non-interventional registry to assess safety and effectiveness of adalimumab in patients with moderately to severely active ulcerative colitis (UC)
Action: For adoption of advice to CHMP

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Anagrelide – XAGRID (CAP) - EMEA/H/C/000480/S/0064 (without RMP)

Applicant: Shire Pharmaceutical Contracts Ltd.

PRAC Rapporteur: Corinne Fechant

Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

8.1.2. Canakinumab – ILARIS (CAP) - EMEA/H/C/0001109/S/0042 (without RMP)

Applicant: Novartis Europharm Ltd

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Bedaquiline – SIRTURO (CAP) - EMEA/H/C/0002614/R/0010 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Qun-Ying Yue

Scope: Conditional renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.2.2. Bosutinib – BOSULIF (CAP) - EMEA/H/C/002373/R/0019 (without RMP)

Applicant: Pfizer Limited

PRAC Rapporteur: Martin Huber

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.3. Cabozantinib – COMETRIQ (CAP) - EMEA/H/C/002640/R/0017 (without RMP)

Applicant: TMC Pharma Services Ltd

PRAC Rapporteur: Sabine Straus

Scope: Conditional renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Apixaban – ELIQUIS (CAP) - EMEA/H/C/0002148/R/0034 (with RMP)

Applicant: Bristol-Myers Squibb / Pfizer EEIG

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.2. Retigabine – TROBALT (CAP) - EMEA/H/C/001245/R/0036 (with RMP)

Applicant: Glaxo Group Ltd

PRAC Rapporteur: Doris Stenver

Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

None

12.2. Coordination with EMA Scientific Committees or CMDh

12.2.1. CHMP guideline concerning tools for early access to medicines - accelerated assessment - revision

Action: For discussion

12.2.2. CHMP guideline concerning tools for early access to medicines - conditional marketing authorisation - revision

Action: For discussion

12.2.3. Joint Paediatric Committee (PDCO)-PRAC Working Group - guideline on conduct of pharmacovigilance for medicines used by the paediatric population

Action: For discussion

12.2.4. Paediatric pharmacovigilance - organ maturation tables

Action: For discussion

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

12.3.1. EMA workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOAC) on 23 November 2015

Action: For discussion

12.3.2. Scientific Advice Working Party (SAWP) – update on pilot for non-imposed PASS protocols

Action: For discussion

12.3.3. Working Party with Healthcare Professionals' Organisations (HCPWP)- work plan 2016

Action: For adoption

12.3.4. Working Party with Patients' and Consumers' Organisations (PCWP) – work plan 2016

Action: For adoption

12.4. Cooperation within the EU regulatory network

None

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None

12.8. Planning and reporting

None

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst; Margarida Guimarães
Action: For discussion

12.10.2. Periodic Safety Update Reports Single Assessment (PSUSA) – proactive publication of PRAC assessment reports for nationally approved products (NAPs)

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption of the revised list

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

Action: For discussion

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption of the list

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality - EudraVigilance auditable requirement communication plan

Action: For discussion

12.13.2. EudraVigilance Access Policy – technical implementation

Action: For discussion

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

12.17.1. Conditional renewals and annual re-assessments - revision of assessment report templates

Action: For discussion

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

12.18.2.1. PRAC meeting highlights – inclusion of topics

Action: For discussion

12.19. Continuous pharmacovigilance

12.19.1. Rapid Alert/Non-Urgent Information (RA/NUI) – templates update

Action: For adoption

12.20. Others

13. Any other business

13.1. Strategy on impact of pharmacovigilance

Action: For adoption

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/